Testing a new gene therapy injection for age-related vision loss

This trial is testing KH658, a gene therapy that is injected directly into the eye to help slow or stop vision loss from neovascular age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). Unlike other treatments that require repeated injections every few weeks or months, this medication is designed to be given just once and continue working over time. Researchers hope this approach will reduce the burden of frequent eye injections while helping you keep your vision.

Many people with this type of macular degeneration need repeated eye injections every month or two to maintain their vision, which can be inconvenient and stressful. This trial exists to see whether the medication can provide longer-lasting benefit from a single injection, potentially freeing patients from the cycle of frequent visits and injections.